Updated: Moderna claims cancer vaccine success in trial of mRNA shot with Merck

Drew Armstrong

Executive Editor

An experimental, mRNA-based cancer vaccine significantly reduced the risk that melanoma patients’ cancers would return and be fatal, Moderna and Merck said, in what the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Moderna claims cancer vaccine success in trial of mRNA shot with Merck

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Up­dat­ed: Mod­er­na claims can­cer vac­cine suc­cess in tri­al of mR­NA shot with Mer­ck

Executive Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: Moderna claims cancer vaccine success in trial of mRNA shot with Merck